FULLER & THALER ASSET MANAGEMENT, INC. - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 116 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.

Quarter-by-quarter ownership
FULLER & THALER ASSET MANAGEMENT, INC. ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2018$2,515,000
+7.8%
312,800
-0.0%
0.03%0.0%
Q1 2018$2,334,000
+16.1%
312,900
-7.4%
0.03%
+12.5%
Q4 2017$2,010,000
-38.5%
337,800
-24.0%
0.02%
-40.0%
Q3 2017$3,269,000
+7.9%
444,200
-0.5%
0.04%0.0%
Q2 2017$3,030,000
-28.4%
446,300
-0.4%
0.04%
-31.0%
Q1 2017$4,229,000
+9.2%
448,0000.0%0.06%0.0%
Q4 2016$3,871,000
+36.5%
448,0000.0%0.06%
+23.4%
Q3 2016$2,836,000
+45.8%
448,000
-2.8%
0.05%
+42.4%
Q2 2016$1,945,000
-3.2%
460,900
+0.0%
0.03%
-15.4%
Q1 2016$2,009,000
-46.1%
460,800
-24.2%
0.04%
-51.2%
Q4 2015$3,726,000
+12.6%
607,900
+5.0%
0.08%
-7.0%
Q3 2015$3,310,000
-23.3%
578,700
+0.1%
0.09%
-29.5%
Q2 2015$4,314,000
+27.4%
578,300
+2.1%
0.12%
+13.0%
Q1 2015$3,386,000
-21.1%
566,200
-0.3%
0.11%
-30.3%
Q4 2014$4,294,000
+47.9%
568,000
+1.5%
0.16%
+24.0%
Q3 2014$2,904,000
+20.4%
559,5000.0%0.12%
+22.5%
Q2 2014$2,411,000
+16.5%
559,500
+10.6%
0.10%
+2.0%
Q1 2014$2,070,000506,0000.10%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q3 2016
NameSharesValueWeighting ↓
Broadfin Capital, LLC 8,951,169$54,871,0003.38%
Virtus ETF Advisers LLC 103,807$636,0001.75%
BKS ADVISORS, LLC 291,150$1,785,0000.92%
Piermont Capital Management Inc. 363,549$2,229,0000.71%
TUDOR INVESTMENT CORP ET AL 2,370,760$14,532,0000.41%
SEARLE & CO. 60,000$349,0000.34%
TURNER INVESTMENTS LLC 252,785$1,550,0000.32%
RICE HALL JAMES & ASSOCIATES, LLC 891,672$5,466,0000.31%
Phocas Financial Corp. 635,333$3,895,0000.30%
TFS CAPITAL LLC 398,283$2,441,0000.26%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders